Home / Medical Devices / Lyme Disease Diagnostics Market - Growth, Future Prospects & Competitive Analysis, 2018-2026

Lyme Disease Diagnostics Market - Growth, Future Prospects & Competitive Analysis, 2018-2026

Overview:

According to the American Lyme Disease Foundation, Lyme disease occurs due to the bite of deer tick which through its bite transmits the infection of Borrelia burgdoferi a type of spirochete bacterium. The bacterium travels through the bloodstream and settles in various body tissues. The clinical manifestations of lyme disease are circular skin rash (erythema migrans) at the site of bite, fever, headaches, muscle & joint pain and lethargy. As per the latest research findings of the Bay Area Lyme Foundation, in the United States, every year approximately 329,000 cases of Lyme disease are reported. It is rampantly growing in Northern Midwest and California in the United States and Western Europe. Lyme disease is caused due to four bacterial species such as Borrelia burgdorferi, Borrelia afzelii, Borrelia mayonii, and Borrelia garinii. The key drivers responsible for the growth of Lyme disease diagnostics are rampant spread of Lyme disease and rising public health awareness resulting in early diagnosis and treatment.

According to the research findings of the World Health Organization (WHO), Lyme disease usually occurs in summer. They are prevalent in the forested areas of U.S., Asia and Europe. The disease is fatal as it affects the central nervous system and arthritis usually develops within 2 years of infection. Currently, there is no prophylaxis available for Lyme disease; avoiding deer tick infested area and exposure is the best precaution. The diagnosis of Lyme disease is very sensitive and critical, approximately 55% of the current diagnostic testing solutions is inaccurate and more than 20% of the patients receiving treatment in the early stages of Lyme disease continue to have symptoms. Doxycycline, cefuroxime axetil and amoxicillin are currently prescribed for the treatment of Lyme disease. In July 2017, the USFDA gave fast track designation to VLA15 a Lyme disease vaccine candidate developed by Valneva SE.

The lyme disease diagnostic market is segmented on the following bases:

  • Technology
    • Serological Tests
      • ELISA
      • Western Blot
    • Urine Antigen Tests
    • Lymphocytic Transformation Tests
    • Immunofluorescent Staining
    • Nucleic Acid Tests
  • Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • GCC
      • Rest of Middle East and Africa

Key players identified for Lyme disease diagnostic market includes:

Abbott Laboratories, Inc., Alere, Inc., Bio-Rad Laboratories, Canon Life Sciences, Global Lyme Diagnostics, Graphene Frontiers, Oxford Immunotec and Trinity Biotech.

This report offers:

  • Market assessment is performed by considering the market size for base year 2017 and compounded annual growth rate for the forecast period 2018 to 2026
  • Market size and forecast is presented for the period from 2016 to 2026
  • Competitive landscape gives brief insight regarding the existing competitive environment among the key players actively engaged in the diagnosis of Lyme disease
  • Attractive investment proposition by geography is given by taking into consideration vital facts such as market size and CAGR of different diagnostic technologies and the prevalence of Lyme disease in the geographical regions
  • In the company profiles segment provides insights into product portfolios, financial performance and key developments of the major players offering diagnostic solutions for the detection and confirmation of Lyme disease
Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients